Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...
The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's ...
Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
GlobalData on MSN10d
MSD and Eisai’s LEAP gastroesophageal cancer trial sees mixed successMSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...
In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...
In recent health developments, Akero Therapeutics' drug shows promise for liver disease, Eisai/Biogen's Alzheimer's drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback